Disease Landscape and Forecast Insights

We expect the ulcerative colitis (UC) therapy market to grow steadily over the next decade, primarily driven by the increasing use of non-tumor necrosis factor (TNF) biologics (e.g., Takeda’s…

The introduction of the immune checkpoint inhibitors Keytruda (Merck & Co.), Opdivo ± Yervoy, and Opdualag (Bristol Myers Squibb), as well as BRAF/MEK inhibitor combinations such as Roche /…

The treatment landscape for bladder cancer and upper tract urothelial carcinoma (UTUC) continues to evolve with the expanding role of immune checkpoint inhibitors and novel targeted therapies. The…

The market for multiple sclerosis (MS) disease-modifying therapies (DMTs) continues to fragment as newer entrants in established classes such as TG Therapeutics’ Briumvi, Novartis’s Kesimpta,…

The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 722 currently available and novel biosimilar products, detailing…

Heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure cases. Even though physicians’ understanding of the disease’s pathophysiology…

Drug treatment of heart failure with reduced ejection fraction (HFrEF) is well established, backed by a wealth of supporting evidence from clinical trials. RAAS inhibitors and beta blockers are the…

Doublet or triplet chemotherapy alone or in combination with angiogenesis inhibitors remains the cornerstone of treatment for metastatic colorectal cancer. Patients without RAS mutations also…

Two types of pharmacotherapies are used to treat adult asthma: rescue drugs and maintenance therapies. Rescue drugs are inhaled therapies that treat the acute symptoms of asthma via bronchodilation…

The renal cell carcinoma therapy market is rapidly evolving and experiencing substantial growth, largely driven by the increasing uptake of immune checkpoint inhibitors. Combination regimens,…

No treatments are approved for nonrelapsing secondary-progressive multiple sclerosis (nrSP-MS), an MS disease course in which physical disability accumulates in the absence of superimposed relapses…

Chronic heart failure (CHF) manifests as impaired cardiac function and consequent failure to maintain sufficient blood flow throughout the body to meet its metabolic demands. The CHF therapy market…